Twice-daily radiation linked to better quality of life in lung… | HappeningNow.news

Health · 46 views

Twice-daily radiation linked to better quality of life in lung cancer trial

Previously, the primary endpoint results of the NRG-LU005 (NCT03811002) study assessing the addition of the immunotherapy drug atezolizumab (Tecentriq) to standard-of-care concurrent chemoradiation for limited-stage small-cell lung cancer…

Source Summary Published August 30, 2026 Brief Under 1 min brief
Story intelligence
Coverage Single outlet Single-outlet story
Views 46 Community interest
Brief read Under 1 min brief 81 words

Summary

Previously, the primary endpoint results of the NRG-LU005 (NCT03811002) study assessing the addition of the immunotherapy drug atezolizumab (Tecentriq) to standard-of-care concurrent chemoradiation for limited-stage small-cell lung cancer were reported at the American Society for Radiation Oncology 2024 Annual Meeting. Those results showed that adding atezolizumab did not improve overall survival (OS) for this patient population. At the same time, an exploratory analysis reported a longer median OS among patients who received twice-daily radiation, though the RT schedule was not randomized.

Read original at Medical Xpress

More from Health

Continue reading recent Health coverage

Support HappeningNow

Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.

Support HappeningNow

Report an issue with this page